Highlight Therapeutics has presented positive Phase 2b topline results for intralesional BO-112 in localized basal cell carcinoma, selecting the data for a late-breaker presentation at the European Academy of Dermatology and Venereology (EADV) Congress.

The announcement positions BO-112, an intralesional therapy, as a candidate for localized basal cell carcinoma — the most common form of skin cancer and a diagnosis dermatologists manage daily in clinical practice. The late-breaker designation at EADV signals that the congress scientific committee viewed the topline findings as among the most newsworthy developments in the field this cycle.

The Phase 2b design and the "topline" status of the readout both matter for interpretation. These are headline results from a mid-stage trial, not full peer-reviewed primary data; detailed efficacy figures, safety tables, and durability outcomes will come with the full dataset and eventual publication. Until then, the claim that can be made — and that the company has made — is that the trial met the bar for "positive" topline results in localized disease.

For context on the therapeutic approach: intralesional therapy aims to deliver an active agent directly into the tumor, an appealing strategy in basal cell carcinoma where surgical excision remains standard but is not always feasible or preferred, particularly in patients with tumors in cosmetically or functionally sensitive sites or those unsuitable for surgery. Highlight Therapeutics' broader BO-112 program centers on the agent's potential to induce antitumor immune responses, an mechanism class that has drawn growing interest across cutaneous oncology.

What dermatologists will want to see next from this program is concrete: the primary endpoint result, the histopathological clearance rate if complete response was assessed, the safety profile in the treated cohort, and how the intralesional approach compares with established modalities — surgical excision, Mohs micrographic surgery where indicated, and topical or radiation alternatives for nonsurgical candidates. Sponsor characterizations of "positive" results require the underlying numbers to be weighed, and the full EADV presentation and subsequent publication will carry that detail.

The next steps for Highlight Therapeutics will be disclosure of the full Phase 2b dataset and confirmation of the development path toward late-stage trials, which will determine whether intralesional BO-112 can move closer to a registrational position in localized basal cell carcinoma.